This study investigates the effect of an investigational medication on adults with Amyotrophic Lateral Sclerosis (ALS). ALS is a condition that affects nerve cells in the brain and spinal cord, leading to loss of muscle control. The purpose of this study is to see if adding the investigational medication to an existing treatment can slow down the progression of ALS symptoms or extend survival time.

Participants in the study will receive either the investigational medication or a placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will involve regular monitoring of ALS symptoms and overall health to assess the effects of the treatment.

• Who can participate: Adults diagnosed with ALS who had symptom onset within the last 2 years and have been on a specific medication for at least 4 weeks may participate. Participants must not have been in recent ALS trials and should not have certain medical conditions or histories, such as diabetes or active infections.
• Study details: Participants will be assigned to receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study involves regular health assessments and monitoring of ALS symptoms.